<SEC-DOCUMENT>0001144204-12-010035.txt : 20120221
<SEC-HEADER>0001144204-12-010035.hdr.sgml : 20120220
<ACCEPTANCE-DATETIME>20120221114757
ACCESSION NUMBER:		0001144204-12-010035
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20120216
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120221
DATE AS OF CHANGE:		20120221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Apollo Medical Holdings, Inc.
		CENTRAL INDEX KEY:			0001083446
		STANDARD INDUSTRIAL CLASSIFICATION:	BLANK CHECKS [6770]
		IRS NUMBER:				87042699
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0131

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-25809
		FILM NUMBER:		12625705

	BUSINESS ADDRESS:	
		STREET 1:		450 NORTH BRAND BLVD.,
		STREET 2:		SUITE 600
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203
		BUSINESS PHONE:		818-507-4617

	MAIL ADDRESS:	
		STREET 1:		450 NORTH BRAND BLVD.,
		STREET 2:		SUITE 600
		CITY:			GLENDALE
		STATE:			CA
		ZIP:			91203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SICLONE INDUSTRIES INC
		DATE OF NAME CHANGE:	19990413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v303270_8k.htm
<DESCRIPTION>8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>THE SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Date of Report (Date of earliest event reported):
February 16, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>APOLLO MEDICAL HOLDINGS, INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact name of registrant as specified in its
charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; text-align: center">Delaware</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; text-align: center">000-25809</TD>
    <TD STYLE="width: 2%">&nbsp;</TD>
    <TD STYLE="width: 32%; font-weight: bold; text-align: center"><B>20-8046599</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">(State or Other Jurisdiction</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(Commission File</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">(I.R.S. Employer</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">of Incorporation)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Number)</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Identification Number)</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">700 N. Brand Blvd., Suite 450, Glendale, CA
91203</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Address of principal executive offices) (zip
code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(818) 396-8050</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Registrant's telephone number, including area
code)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">450 N. Brand Blvd., Suite 600, Glendale, CA
91203</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Former name or former address, if changed since
last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Wingdings">&uml;</FONT> Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Effective as of February 15, 2012, Edward &ldquo;Ted&rdquo; Schreck
was elected to the Company&rsquo;s Board of Directors. Mr. Schreck was also appointed as the Chairman of the Board of Directors.
In connection with his service to the Company as a director and Chairman, Mr. Schreck entered into the Company&rsquo;s form of
Director Agreement which entitles such director to receive a combined $30,000 annual cash retainer for his board service as well
as an initial option grant of 1,000,000 options. These options will vest evenly over a 3 year period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 7.01 Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On February 16, 2012, the Company issued a press
release concerning some of the matters discussed above. A copy of such press release is being furnished as Exhibit 99.1 to this
current report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The information in this Item 7.01 of this current
report on Form 8-K, together with the information in Exhibit 99.1, is being furnished and shall not be deemed &ldquo;filed&rdquo;
for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that
Section. Such information shall not be deemed incorporated by reference into any registration statement or other document filed
with the SEC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01 Financial Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(d) Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">99.1</TD><TD>Press Release of Apollo Medical Holdings, Inc. dated February 16, 2012</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold"><B>APOLLO MEDICAL HOLDINGS, INC.</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 51%">Dated: February 16, 2012</TD>
    <TD STYLE="width: 3%">By:&nbsp;</TD>
    <TD STYLE="width: 46%; font-style: italic; border-bottom: Black 1pt solid"><I>/s/ Warren Hosseinion</I></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Name: Warren Hosseinion</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">Title:&nbsp;&nbsp;&nbsp;&nbsp; Chief Executive Officer</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v303270_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-family: Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; font-size: 10pt; text-align: center"><img src="logo.jpg"></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: windowtext 1pt solid; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">February 16, 2012</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Apollo Medical Holdings, Inc. Names Edward
&ldquo;Ted&rdquo; Schreck Chairman Of The Board</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">GLENDALE, Calif., Feb. 16, 2012 /PRNewswire/ &mdash;&nbsp;Apollo
Medical Holdings, Inc. (&quot;ApolloMed&quot;) (OTC-AMEH.PK), a leading provider of hospitalist, critical care and multi-disciplinary
care management services to the healthcare community, today announced the appointment of Edward &quot;Ted&quot; Schreck as Chairman
of its Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Schreck is a senior health care executive whose career spans
over 37 years in both the private and public sectors.&nbsp; He joined Tenet Healthcare Corporation in 1998 as CEO of USC University
Hospital and USC/Norris Cancer Hospital.&nbsp; Under his leadership, both USC University Hospital and USC/Norris achieved significant
growth and clinical program development.&nbsp; In 2000, he was promoted to Regional Vice President of Operations, charged with
leading a group of ten Los Angeles-area hospitals.&nbsp; Two years later, he was promoted to Senior Vice President of Operations.&nbsp;
Mr. Schreck returned as CEO of USC University Hospital and USC/Norris Cancer Center in 2004.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Prior to joining Tenet, Mr. Schreck worked for the St. Joseph Health
System, serving as CEO of Santa Rosa General Hospital and Senior Vice President of Santa Rosa Memorial Hospital, and for Sutter
Health System as CEO of Delta Memorial Hospital.&nbsp; He also served as CEO of the Eden Township District Hospitals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Schreck retired in 2006 but returned to work as a consultant
for Portland-based Legacy Health System, which operates five hospitals, a research facility, a hospice agency, and specialty and
primary care clinics.&nbsp; Most recently, he served on the board of Los Angeles Orthopaedic Hospital, a member of the UCLA Health
System.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Mr. Schreck earned his Bachelor's degree at UCLA and holds a Master's
and Doctorate from USC, the latter from the Price School of Public Policy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&quot;We are honored that Ted has joined our Board,&quot; stated
Warren Hosseinion, M.D., Chief Executive Officer of Apollo Medical Holdings, Inc. &quot;He has a proven track record of success.&nbsp;
His extensive experience in hospital and executive management make him an ideal leader for ApolloMed.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&quot;I'm delighted to be a part of the ApolloMed team, and excited
about their vision for integrated medical management services,&quot; stated Ted Schreck, Chairman of the Board.&nbsp; &quot;ApolloMed
is a pioneer in developing new strategies and innovations for achieving effective, high quality patient care.&nbsp;I believe ApolloMed
will make significant contributions for its patients and its hospital, medical group and health plan clients.&quot;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>About Apollo Medical Holdings, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">ApolloMed is a leading provider of integrated medical management
services that improves the quality and efficiency of inpatient hospital care plus multi-disciplinary care management services targeting
inefficiencies in healthcare payer and provider networks. The Company's integrated model combines hospitalist medicine, critical
care medicine, 24-hour physician call centers, case management and transition management that offers to help healthcare organizations
engage in performance payments for utilization efficiency, quality of care objectives and shared accountability arrangements. The
company's strategy is to capitalize on the growing market for hospital-based physicians and care management services.&nbsp; There
are currently 4900 acute care hospitals in the U.S., with more than 35 million annual admissions. Total U.S. spending on hospital
care currently exceeds $650 billion, and is expected to increase to $1.3 trillion by 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For more information please contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Media Contact</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Nidia Flores</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">818-396-8050</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`/@$'`P$1``(1`0,1`?_$`+@```(!!`,!````````
M```````)"`,&!PH!`@0%`0$``04!`0``````````````!@,$!0<(`@$0``$#
M`P,#`P(#!0,("@,```$"`P01!08`$@<A,0A!$PDB%%%A%7$R0B,*@187H;'!
MX3,F=K;PD5)BHD-C-C<Y&2DZ$0`!`P($!`,&`P8#"0`````!``(#$00A,04&
M05$2!V$B$W&!L<$R%)&AT4)28B,S%?#"%N'Q<I+B0W-$-?_:``P#`0`"$0,1
M`#\`W\:;0/VZMHFBV)!XKS,.JAY+XM]O=JQ^`_<[M);BQ&DJKO("G%=:(0.Z
ME*.LE%:RWA$,;2[+*N'X+Y)<QMB/416F55A)?-C=P?#-EC)9C%5!)>ZK6BM-
MX2>@]:?EJ1V.TXPSUIWCJ/"K@1[<%A7ZL&M]*,4(]GZK(=@R_P#4$(2MPN!9
M.Y:T[36HJ`/P![:M-1T<P`F"M.&95[I\\DCAU!7XT4J3N10A77I^=#UKJ*EE
M]&Z@(Q/)9:9[V.Z>DG!>I%/P[ZJ`ST\]/P5+K+LP0NX'754.#AXKZ<EVT7E&
MB(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1=5]O[1
MKZ"!B5Z;FNIZD?\`3TU3C>[I+GX-0$#RUQ7`(ZU_"@_;JS@E:Y[W<`"OI-*>
M)5$D$;0L[PDIZD@&G4JIVZ?CJK<$R3M:WFJ1/5&3[4KKGOFES*^0;ICT"4\,
M9Q:0NU;6GR&9UW9=4S-6XVA6QQMA]!"2:T&MX;3VTUNE"^E:#)(*\,!PX5RS
M'-0+4M4<RX,8.`\2O%C>3I;0RXAYL!H)05NT6HFH`H.I].FKZXTY@;UL-*\,
M*+[;7,+C67/\5(G'+_,;CKN+LMJ)!92VO[^YS8]LB.I/5]#*YB@VI3'KM%=1
M>ZA>WRO'5CD*DCW!9UFK6EHSJ'P66<9YBXXN3KL&#R-B%PD,N)97&BY#!6\V
MX$I"D...K]M2PJO[O34.O[:[<\/MX'=&-:M(Q\*#*BN;;=%A<5:\CU`?R]Y6
M:(DR/*:0]&D(D-+2%(>9<0ZVNM:['6RI"P/RUA9FW,?]1@!]]5D&W]O/_3*]
MR"2H_L_TZLK>422EO$!5P#GP575XOJ-$1HB-$1HB-$1HB-$1HB7EY]_(AQWX
M!67`[UR%A669A%SZZR[3;V\5E0H[\:5$8,@AX2Q5:7$)--I';1%4\1?D'X_\
MO^!.0_(##\-RW',<XYG7>!<K'>9,&1>)<BQVEN\R?MS$0D)#D=U(`63U/X:(
MH;>-GSL\#>3?.W%W`N+<5<CV"_<J7Z38;9=[Q+MCMMA28]GN5X]QYN*D2/:7
M'M:Z$;1^.B)Y;9<J@+^JJ%%3B%'9O2K:$A->FY*J_G31%7T1&B(T1&B(T1&B
M(T1&B(T1&B*Q.3\Z@\8\?9=R#<XSLRW8A8YM^G16%H;?>C0&RZ\AI;@*`X4#
MI7UU=V-G)J%Y'914]21P:*\RK'4KUNGV,EX[Z6"OY@?-1-\??.7"O(/D%6`8
M_B]^LUP%CN-_^YNDF*MA<*VNPF'4I0RD++BESD4'IJ1Z[L[4]$L1<7P8V)YZ
M1TN!Q.*B&C[JCU+4OMHZUH3C7(*<W^A5/\^H)%;.8UWBT_!3R7]G_B"^5/4M
MN#<'=Y^F%+6T``%`ICN$H2H4-:C]NKZVBC+F2%O\SJS]ZHRO:-.?(SZPUWSH
MM<^VY:[/N$ZXR=VZ9+EN2RX3O#TB0XX^5)/_`)A6HU/<:[)M]-C&V87VC2"6
MLJ<3F/-F>?\`L7/D&JW5QJ+FWK^H=1I@!D?`)B'BOQF<[<D97>6UNXQ;I*(T
M%IW<VBZS4M!3B:I4VKVX@`-4]R:&NM+;QUJVTE[[&U'3>M.)K6F1Q!!'%3[2
M-(N;NX^Z?4VS\0*>SC52AYN\8^+^;+*W$R6!+@7&UH]FQW6VRYC9MJNB$.?I
M2'C:YB%5HKWF5]/4:UYH6]=9TVY/1,?2+B2"&DDUYEI/R4HU/;-A=6_2V/\`
MF4SJ<O95).YC\8LBX9R-5GO,&-*MDPJ-EO<1NJ9<(NE*75[3LBR=]:H1M`/I
MKI_:F[;?7-)<][ZR!]#CB,*X@`+4&J[<NM+F\@(KCE^I*OGA+GGE#@^Z1(\"
M]3[]AJ'4-W7&;FY]]'+**D/6]^4EV7#>82M1V,+;#E1O!VIIA=S;0TC5[:6Z
M;'34"S!_4\TI_#U`'C^*N-#U34;6<1OD_E<J-_1/.XQY#L/)^*6K+<=?+\&Y
MQ0XMLT#D*2V0A^')1T6V^A9[$=0*ZYAOM(=I>IR,=RI[<<\SFMUZ=?"\A&-7
M`8^'Y*_WW$M-E:E^V$D'=M*AW[*`2H[3ZTZ@>NJ2R"2YY8?.%XL>,6:W;C"V
MLY%S%R%8E);OL/#F&XF,V>6R\N+<;9,R*2W)3'GPG&"5(#+WU+">HZ@BPOP]
M_44>*6<Y/;+#R+@_('$]ON\PPXV23_M,DM,"JVFT2[^Y"CVY^TP4?6I;OMN4
M0DD)/;1$WOFSR?X^X-\?,D\EKY(F9+QGCF.1\G3-Q%MF[2K_`&::EI<*;9FR
MIA#JGD.@A)/;1$L?%/G^\(\BQ'D#+9)Y'QYO!XMMEQ+)D.+QH^0YDN_.2/TV
M'C4*/=%H6Y'#8#Q</\L'KU!J16/P[_4+^,?(^>6W#<TX_P`ZXFMM]NHLUKS.
M[2(%^LT68ZZAF(_?HT5FW2K=;Y"W$A3J"\EM1(J:5T1/?N^56*Q8W,R^[WZV
M6O&H%I-]EWV8ZA%IC6E$;[A<]V25)`C%I06#NJ1VKHB0MS!_44>*.`Y//Q_C
MK",ZYBB6^5)CR<C@2H6,V)[[1PIDO6>1+@7*1<H;*!N]PMM@GH"1UT12-\.?
MF?\`%KS`S2V\8PE9!Q?R1?&EO8]C^6B&JUY`G:L);M62-I1#D2W*I]MDH2XI
M0/2E`2)>_P#4LN.CC[QL^M:",QR0_2=A"DV26`JJ*$+IWIVT17)\&XW_`!K>
M3V^J_P#>CD5LE7U%2$8'$;2%$]5'9TJ>IT1(*^(E/_['_$0@I2&N0;FT"2H4
M:3@.9(0A(!H5%1`ZUKZZ(MY_RR\U^!/"S"&,WYORY=H3<&Y`L6*6R&;KEF1R
M(S86\S9+4VZTI\Q_XUJ(2D&OU4IHB3:W_4H^/:[\F,>"N3!CGWBVG+V+O:G9
MBH>PJ9DQ+,W;_<<>-1O:4\"DBE1HB=;XM>7G"?F/QNQR=PAE3=[M"'TPKS:Y
M38AWW'+ILHNUWNWJ+KD=T+)((H%`5!]-%\)H*G(+"UR^1GA>T9Q)P.XQ,MCW
M6%D;V+2IR[0T+*B=&FF*\^)!D!SVA3H:TULNT[5;HU+3/OK"-[VF,.!#1F14
M-Q>,^:US>=Q]*M=1%HX#IZB#YO=7Z/FK(RWY2>([#?W[38L5R3*[?$<2U*OD
M=^+;8_N5VNIB0WV9$B1L/K4`ZR.D=F-SWEGZUV7QW&/E,8)'O$E%9ZCW3TBQ
MF#>EICPQZZ?Y"LK3O/[@R#Q5;>3OU2\/MW":NV,XRF$Q_>5-R944/LR8)4@)
MAH=20'Q1*TT('76#;VWW(W53ID\$C&AQ'60VG34@.H'<:956;C[AZ!-:-N8R
MPES`:=3L,*T^E6'Q;\EG%O(&76_$KSCU[PQR]7"-:[/<9[C,F&_,DK=;:;?<
M;;2(P6I`ZJZ#=J1;A[-Z]H6D_P!U!=/$!4@1AM!Q-3(?@K'3^XNDZA>BT8YH
M<33ZB?\`(%.K-.0,>X]QZ;EF7W>%8\?MS`=DS9:T[75.=66H:@4^ZZX!]*=I
M))UJ32K'4-=O_P"U:9$Y]Z[!H%"2?`$@>.:FNIZI9Z18?W*\>UL'C7E7,`_!
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MV9D6;(7`46F'I['M)8D/.$)0C82H]-3_`$WM?N/;NOV>IR=<UC'<-]2C`T,Q
MS)ZR?P"U]J^_M-U[3I]+@`9+)$2T]756AKETCES48_C,`'DXI"TEQW_#?+G7
M3N52,^Y<L?;>:3U`VK+(-.PITU..\\1BVY#PI./@HCVR>Z;7CZN/\O\`5;#Y
M`Z$?]KK^8URK%<=;'$GS"OY+I8@.P=D,O:K(OMT;96F,M10T2=[M?Y>U22E2
M3T[%)-=2"RMQ0DC@L7Z4DL#HAE0\^*UUN7\6NW&'-&98@\VHP?UUZ\8Y0%*)
M=AO#HN%KDI/034LL2`RZE`3_`#$GMVUUKL+6(M0VR&REM65KEA0>)*Y]UC3Y
M++7'1BH!)Y\3[`MA+AS&(.+\881:H;/M-HL%NGN)"4I5]Y<&$SY+B_H2?<WR
M2CKU"4@>FN2=RWCM2W#=W+OI=,Z@\!1HY\`M_P"C,,&DP,(\PC'YX_-9,":E
M5"H%2J[A3<GJ.@J#1)IK"^BQN+<"L@)'G!PP]BP9Y`\:0N0\!NT93+:KC:HK
M]RM*Z)"TR6$*<6VHE"E*86D5*01UZZDNT];ETF_$(=2.5P!%<,,CF,:\>2Q^
MK645W!UO`ZFCD/T2@$X4@I946`HE*I``Z%+CBU-$D4[H4R=M>P)UTQ9Z@R6P
M\_$>'ZK4EW9>E<^0<?\`'!33\-;C<,9RB\8BMU2+1>[;(GQ8BJ*0F],.L+]U
M'[NQ*H@<!`H">NM.=QK*W9;Q7T0`D,W1A3(M<<:#PYJ<[4,GJO:[Z?3\>83`
MLO:NLK%LFB6)Z/'O4BPW:+:I$J08D:/=)-ND-6]]^4&WE1V6I2TJ4H(60!T!
MUJ=39:E'B_\`"/R=QIY!6CEOSMR+A3(^'(4B]9%FK5PY(NT(WW)G2ZY&G7<W
M2QV%B5;7)#ZUN[I3:5K0CJ*441+S^8RV>'UH\E[3"\0CBD>RMX$W"SZ+@KJY
M>)/W^-+/V:X$A2Y42X.+@.K#Y:=VA02>M""1.HFW:Y7G^G7CR;K-D7"7$X<B
M6YJ5)<4Y(4Q`OR6(I6X2*N-M`)J*"@[:(DD?#QXD<<^7WEM'P[F"V2LBXVQ+
M";[G-[L;<TP472[Q)5LBVNW7*2PV)2[*\N=(#K+:VED`;7$TZD5Q_-!X=<7>
M(/E!9K#PGCR<0XUSOC>W9!9<<;GS[@U8KU^N2(-YC6:3<'Y,YBV^W&9=;;==
M>4AQ1.^AH")E?E9Y69>?@D\>7G\EN1R[E<XIQ3>[TATF?=8^-O3)=V9D/A16
MDS+=:MCM.JT`CIHBQ!\`WA=P+Y"Q.?>6.9\#L/(<;%KA8..\;L^0-R3`M`=M
M3=]N,AB#&>CM*]Z+/;82I14:(-:GKHB57YPX!`\+O/WE7&^,&'[%:^(^4[-E
M_';,-;OM6*-+@V3,K>Q"W;%*APG+HN.4J*JMM;:FE=$3L_Z@G)',Q\<_"S+'
MG7'W\D;%[DNN)2E3DJY88)<EPI2``5/NJ[=*:(LQ_!K_`/6OY/?\6<C_`/(T
M31$@KXB5!/R/>)%21NY%NB:"E"3@N8T"J@U`(KZ=1HBD'\[7+5[Y,\^LSQ1V
M\NO6'ANR8WAEGMBRK[&S767;_P!>NMS0R%!1G/MOI#JP0%-_331$XKG7XK_&
MG#?B@OERQGC>SHYDP'A<<IQN08CDQ&1W?*(%N&0SF9,I3ZDNP+B%*:+1138!
MU!J=$2V_Z=KDZ^XSYF91Q>V_(9QOE+B;*LANL%3@5".1X;/L?V$EEA!0VQ*<
MB3G@ZK:HK-.W709KX[Z33DI6<HPE7SR!SBR%/L??\ESH<9PE0:;<GY&IAUU/
M7H\$GZ3Z'T.N\=MW$]GL#[N`-=TV[3@*_L@</U7&>JSQR;P;;NZ@#*1RYE,)
M\U/%3AKAK@7'<JP/&G+1D<.\62WO754Y^7)N3=Q2#+5<3*#B'5J4H[2@-[=:
M>[<;[U[5-S/L;M[70R9-Z31IK3#S8#G6N.2V=O3:FF6^CLN\0<*FH_=K^ZL2
M?'YX^\=<UY#R!.Y(M;F1V;%H5K_3+'(GRV;;]]<WY+<F1(;8<;D.+;]L;-KJ
M$I/H>VLUWNW+<::;2+3:13O:>IP%'>4\P:_BL7VTVM'K3I_5<3`P^4=1Y>P_
MDHJ^0V)6?BSG/D?&,.9<MUKQ;)&T6ALO./K8HU;[DPOW7%$^['<7L0I.T^V*
M&IJ=3O;[]1USMP^\OW-=6W_BRPYU48US3(]M[P;:P/Q]3]ZOR;\$PGY+,ZN"
M<5X$P5<EY,&]XZG+KDE*E!I]ZUP;8PA$RI.]ITRE43ZJZUUIWLM96K-6NKTL
M!N(Y.EIH",S7A6OL(4Y[K75W_:X+9CB(71M+@":_3[5XO#[`/$R;P&_)Y<N&
M$.YUE$_(&UQ\CN\2%=;)&8>?@VUBWLNR8[K22AH.E0"DEPG]FJO</7]Z.W:8
MK`7(LHB``QLG0\$UQI4988$*OL:';?\`I-OWX8;IP-2[T^H&F8ZL?Q44/$^^
M?X;^5V&P[5</?M:\OON,.O6YY4^-<K++-S9B%Q:?:1MJRP0HE=0#TU.]Z6L%
M_L2078;]ZV$.!H*AP(/&KLO>H)M&6[L-ZEU@7"VDDH<Z=(!/"@S]H7I\\LLD
MY1Y-<BIENN/*Q%X8I:PM:TH@,P[<S*]N*A*P$AZ1.!6?XMH[4UX[,VS]/V3<
MW]`'2"0@D8X#V#CXJ0=T;J2_W#!IY=@'-!`/,D<SC[E-GF#PEXEP[Q(EY3:<
M:>A\BXGA\/+YU^_4YBY$J2&VI=R:G-*68[S7MDA*=@*1Z^NM<;9WOJE[O5NG
MWTH=ILTY9TXTZA])%2<S@<PICJ6S++1]JG4F`_>,C!KAQP/[(.1YJ-?QEND^
M3K:5_OO<89@]4"A76]619+G4[E@N?ETU..^DL;]M0]`_]CP_=*AW:[_[SO\`
MQ_JMB"G3^W7&L$<E'^_X%=-*.677(*;6RI]1(W5:/T_^+]ZG76R;*+[C"G2"
M."L?OQ!4A@-1S*A=S?Q_8N7K?;_O)D>PYYB"_<P'+92$"VE+4U+J\>OSA*7/
MM75@E#@J0#0"FI_H%]J&VXY(+<"6SF#NL$]):>F@<*5KRHH!K6CVVIW_`-])
M(8WUR`J,ZYE,XQ%]9Q?'D/R(TB6W9+6S+=@*]V*Y+:@L-RU,+2-I9^X2K;^6
MM+W=O(;V24G`O/Q4YT^>(0,BXAH'X47W_>*%D*"@@"JG"0$)IU())'4#5)\3
MG,\A\RR$LT#!B<?8L0Y)S)@L'*;'@*+I%NN1Y.9\5BW6Y]N4Y%CL,'[V5-2T
M5^RTT%`?535SI^A7DDG]P>2V*.M,L<O&JP\^HM>#%&`1D3C^BAE)PU"')?VS
M*"EJ=)0VM*:MKCJ<+C12K\4^X:@=-;GBU>2&(04P`I6I_11*;33-+ZI-#6M,
M%E'A;%EPN1K)-:3O1%BW-Q]6P)"`[;Y#":D?]]P4_/45WGJ!N]-BB(RGKQ_=
M<I!HD)AE<W^#YA9\Y\Y0C\-<%\I<MRXS<MGCKC_(LT4R\L(;>=L=LD2VD.DU
M'M^XT*U]-:W4D6B?P9CODW\PGETK!N2N:[W:3<+3<\XOK\R[/2+1B>"6A^)#
MEHQS&(\YN!,=;-Y890RZ=I+NY1`%=$57Y5O`_BOP'SKA_C;C6]95DB,@P:[W
M[(;UE$J.#,F-RA'CO0H$;?!M;2B?]F'EJ5V`T1.G8_\`YTCV_P#BL]S0?^Y!
MW/H-$4"_Z<>]Q+=Y=<F8_-3'3-OW#DUR"I<A/N*_3+Y%?DB)L*FGD.HFT/U5
M`:KHBN;^I!O=MD^3/"F/Q76G[E8N'YDR3'9<WOL,WF_N-VI3B#^ZIQZWG:.Y
M2HG\*D6*O)K"KPS\''@]>6'GI$.)SM>\AN,R4W[;4&/D]@R^T0$LD$I<CIN<
MIM#2B1N)T1,@_IK)[(X=\G(OW##DQOE''GO8/ML+:BKQ.!&:=?:4H4]UYM0!
M'3I2M=$23_FRO;%^^17R(%L4@_W;3C-EN+B$5#TAG"K$Z4MFE'I7W%R0T`"?
MJ21W&B)F_P`[,!^V>)'@3!DA0?C6*V-K"T[%C_<%A8#B/X'*+^H>AT12&^#7
M_P"M?R>_XLY'_P"1HFB)!/Q$E'_Y(/$;>3UY&NP105JO^X&:D`_@.FB+ZGR_
MV:=8_D@\IC.;]MF_9E8[Y%!)]QR#,PZQ0V'PE5`6E*@R0GT*A3UT1;F'D[E-
MJLWQE<N9/*F,F#$\4KI+<7%6TXA;+F'!ME4?ZMCBGUJVH`)JKH*F@T1:JGP$
M6UVX_(ECJV&IC#-HXFY,N<@)27&]X=QR(A+ZU%(:8D+<4JO?>FFB&M,,Z)AN
M;!:_):_)<62%<V*"0/IV#^]?[H(J2!KN+9UU%9=L9(WO,U8!]0IF!AAR^2Y&
MO[,W6^6O=&UE+@B@->:<;\E2:>,UM32@3DV,'=ZDI0GO^W7/G:"2%^]PYSB!
M4\/XEN/NA#-_I?HC8!B.(_=HL!_%`&W)/,22D)06<:"Q4G<HORW"OMW*E_Y-
M2CO^R%EW:21O)+NKA2G^]8?LH;F."Y:X8`X&O&B@7YG`#R7YJ'[H&3,].]*V
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M2A[GL$D=`:"H#D\[R6OL*9XA<H7:.^S]K=N*'Q">2ZVIF2Y-M33+##2PKJHN
M&@_$]M<K[7>Z#N%9Z>XGKCN:GV!U2>62WWO.XKLJ69WE:8A@,<7$8)3OQEJ0
M/*!QM2:*3QIE3K:NX0AVX8\%LCI^ZA:.GKK?O>T0,VS`6/+B9\012GE6ENU,
MO5N!S:?]K]5L/*)W)%.FX&O^K7*L;(VPN(/E(*Z?%*$\:**_,L"18YANQ:4B
MVR4A"745*$.TZA0].^IQH,\<E&D^89J-W<$C&&F2ACE5V:W.-;ERVRE;JU/#
MJMTDEM"AT;,9H=$T&ZFMJ6L$<L8<<J*$7\\C">:Q=_B9E&+MH&.9#=+&ZL*V
M)B37P5$$[@25$!.ZM/P&JS-NV>KO-I.VH-.)'P6(.L3V].G,>`6,<Q\@N8KF
MR[!E<E9.PWL476F+JY]NMI*3TD%TE+:U`^O[WIK.VG;G0=&(O7"DC>;WT'N)
MHL==[AU&Y\@.'L"DIX,\1WA<W)N:<CA2?O[E#<L>*OS8[C<A]F:A#UQO84K^
M6\P^D^R"D;MR2>U-0??=_ITMU#:V9;Z08.NAKDXX89$X9\%-ME1W,]E/)."'
M>M05%,.D?-3X5AB0"5,4^E38:92I*"GW75-$;NRPA8"CZTU`KS4Q2HQ/N\%+
MC9N62L)Q.-967)C:-DQ]I3.Y8/T-J6E1'YD[>^HO>7DEP`Q^0-5=VD!B>7'D
MOC<]<80^9.$^4.))FP1.0\%R+$'/<%6S^LVV1$0ETD':TMUP!1]`=6"OUH@\
M.\+_`"+_`!Y>2,G*..>"LT>SC%&+]C'W,'#SDN)Y9C%U=:#S!DH2I$ABXJA1
M7F6Z[D*;%=$5\^97C)\IODI=,!\@^>.)\NR[).2K?>;3:<0Q+&64R./<9QQV
MVN6]%ZQZVAN/:W;TY+6IG</=5["ZFI&B)O\`=;'F6(?T^V5X;R!@^2\>Y9B&
M%7&P7;'LNAFUW%#L'*0VB6&UUV1YB*+17J`:'KHBUT_!G"/+J3GV3<K>&OZ@
M_P`L\&6A.5R8-K1$NUVOF-766N+(M\>T7=+T&ZVX/1@I;02=R>@ZZ(LT9%XW
M_)5\@7D1&R#D_BKD"7R-?56^S7_+<BQ96-XGA]A@2'%1'4AM+,9F'#<DNNEA
MH52"$@=-$6VQS[\=&/<C_&]`\(,6DQFI6$X+C$/!KO<BZIB/E>*2F+O%F276
M*.*,NY(<"J=2E?71%JW^/EO^4CXT.4L^9X[X/S-J;E=N;LV20IF'JRW";\FS
M2Y4BWY#9W6$.):EN(?!!J%)0=BNM=$5]>)/QL^9?FIY.1>:?)3`;]B>`S^0H
MG(W*&4\@156)>3"/.1-&/8]:^DI]"E-M(2*;$-``]M$3:/G[\?\`E[F+CGQT
MLW"7%69<A#%LBNS4^WXA9W;J_:+:FR/PX:Y#+:@I"/;;&T=R!HBNGX<^$N8.
M*_`+R(P7DCC7+\)R^_Y'F\JQXYD5I=M]WNC-SPN/'A*BPW%%:B](;*`.]=$2
M3OB]\-O*_CGSX\7<VSSQZY3Q/$,?SRX3;UDU[QF3#L=NB2<*R^"R^_<%J+:4
MKD26P.G\6B)GGS?_`!B\R\W<A6CRB\>\-5GEUD62TXKR;A-E)7E;T2TR'7+?
MD5HBK4&;@EIA:FG$(_F("MY^E)T1*PR#F#Y9<O\`%FS^$MSX@Y.DX!"1:\3^
MX''3RLQOMAM[X5$QJYW9ULN2(S[E&W"VH%38I7IHB>1\)'QM\D>)\'+^<N?+
M)&QSE#D2S1;#C.)NR?O;]B&+IE+G7&/?%,$Q&[A<Y#;2O;3]3:4@*ZZ+X<C3
M.BQQE?`7-L[R$O-\B<5YN_9GN6A>&;FFR/"(]!5DWNAY#A5U06^M?PUUQH&Z
M=N6VP76,\T8N#`,.L`Y#AFN7-3T/7W[T;-'&\Q^L<>CVIJ?R"8CEN:>/<2RX
MKCUVR&[-7ZPR56^U1%2I"6XX2'BI*.Q03K2/;/4]+TS=/WUR]H@;7'JI^US/
M@MM;_LM4O]O_`&T#'&;D&U_9_588^,[C7/./9?*PS7$;_C:+C^A-V]V[6YV&
MW-$=+CBE,J6?_4'3OJ3][-<T?6GV;K.1C@P.K1P/'#)8?M1I.JZ2RY^^8YH=
ME5M.7-0J\M>">9\E\A>6[W8.,\MNUGN>01Y$*[1+8XJW26/TJV-./1Y6[8\V
MTXA221_$DCTUL[96Z]O6?;W^WSS1BY,-*%X!KAPS4`W7M[7;G>K;UD3S#ZE:
M]&'XY)F?ESXT7SG?AK`7\:C);Y!X_MMHF6R#+2M/WS1M49%PLQVG;[KKC7\7
M0*'76D^WN[K;;&XY77+A_;I7FIPI]6!J<A1;-W[M:^W+M^+[9I^_8T4%"2/+
MC@,\4LCC3,O,?@7$\FXPQ[`,FM5LO,Z>Y(MTG#5W-=LG3V1'E*M$W:I*8SZ!
MO!0=H62>^MNZC:=OMT:P-:GFB,K37^L1B#7@:9K7.E7F^=MZ0-%,,GHT(_I-
MXX9G%2/\#_$WD:V<D1>9N4++.QR#8H<Z1CUNO*4)N=RO5T3)CNSU,M"D=J.R
M\YT5]1+@IV.H[W>[B:5>:##H>D4?Z5>LM<UV%6T%<QE[UG.WVR-0M]7?J^IU
M;ZHJ`0X8_#C^2K_(5XI9WD6;M\O<=X_-R&%<K9!A9-;+0TEZ='EP?>]RY*;/
M\Q8?BN>VGN`H]=4NRG<'2(+.72=9>V.(U#>IS6BA\<SQ53N;L_5KBZBO='8Y
M[V@5HTNQ%3\5'"WV/S=Y7X\D<3?I>2_X<XY;&G%Q+K9&+8N9$MK/NM6Q<M;:
M9+\E3J*-)!VJ/0ZF$\?:[2]Q-W#!/%]P9>$[G8G"M*T`''DHW91;]N[<:5JT
M4@TOH<23$&BH%1YABLQ_'IP_RM@_D.J]9AQ]DN,V3^X.6V[]3O%N<BQES'+Q
M;'([#;Q-'-[+1(_&FL+WIW-MW6M#AATF1CY&S`T#P["A!R]RD7;G0+C3]4?-
M(TAO0<2#X\T]3<-M*]1_KUR^8@0*?36JWM$_J8YO$-*^3=[!#OUOD6VZLM28
MTA*DAM:0KV2H$!39I4*%>^J]A<SV<@D!\P/XCD56G;%*SIIP_-0<Y)\5,J?>
M>G81=X\YJKJC;;@^8JFP5$AEE08=#FQ)H*D:V9IN]["**EVV5KQP:.H'QS%/
M\8J&ZCM^ZN7?R?3Z?$T^2BS<O%SG>>\8L;#VTNEWVVY<F>AN$A"B-R_>#:UA
M/7U1J767<K:MM"TD7/W5,?Y0I6O`]55@)MF:H_Z?1_YO^E9EXL^/SV;E#O?+
M5VBW2+%>3*3B%M=4]"DRD'>E=QN2FF''V@L#^4$[1VKJ/;C[FOU"/T-.]0,(
MS-6T]P<:JYT_9D\3^J[]+I\,?BU,JM]CM]LAQ[?"BL1841IN/$B,--M,1F&4
M!MMEEMM"4H0E([:U3)>7$TCI)7$O)SK4GVJ?65G#91>E$*`FN%/E1>T0F`H*
M#2"4UI7M_FUX,SW"A."N\%Z4IIZ)'3LGMUI^0_#5(FJ^8<%PXC>A2*D!0H2D
ME*A^8(Z@Z^(J#T<.U"TMOH4XTLM2`'&T>UU2IL$='-R0:FM#HBZHCJ2A8)JM
MT)#BUT6HA*U&A("0HA*R`3T%!WT1+W^4[#,JY#\#N?\`#<*QJZ9)E%[QQJ-"
ML-BC";<)KIG,.J]EE*4EXK0DDT%>NB)(/P#^-G/?"WD+RU>>5N(\UXZM,_BZ
M%9K/*R:RN6V$IQN\N3&XT11D..*3[+@K]1.X$#\=$6V0IE;@2%K*D)"%)"%O
M-+*TTZJ6EP;D$?PJ!_.NB+J6552V6FUMU42K>4!-34!3*0$N'\34:(JB6W`3
MUVC<2E6XK6!N[$N!8VK_`"`IHBX"'@H_NA*B/W5+!;`ZF@7O;43^0331%P&5
MI_<"002I*G%N.D*ZI(42H+6"A1IUHG1$!EQ5/<+847/<6ME*FR2B@;KN6O<0
MD4->FB+LII12I/N+.\I_CH4;:&J5)"30[14=/71%RIM9I]7907T.TG\4)4!N
M0*COUJ"1HB[!%$@!"4?BA*BD"IZT*:"O]FB*FIE5"&PVA2B%+71>YP@]-Q0M
M"U4'XDZ(J0BU4HEIH$`%*@!MW[@HJV4JDA0J#7OK[*^0PF.$FOB3\0K2.UB^
MY]>5C2?8/F%S[#H-4EL]*!*]Q0*GJ=H(%::MXHG10.:TGUC6F.%?BKN0B60=
M8!B_-"([G992$I(4GVRL'<.VXDFHUXEADG8ULIR`K0G/WJMU01C^2T`G/`?(
M+AR+N6E8VJ`24EM004D+6V5$[FU5HD']M=7T<CF1AE37#'C@J#XK>3S/8PR<
MRT%<?;+(%0"2LK"2K:&E$]TEI+97T'KJD&C$$GIS\5Y+I0*L#>KQR7)CN4-4
MLN'8*!5:[J^BU;R!37L$Q_TR[/B5Y$,,N-S'&7^#0?B@L.`H6E"-VVBD*<64
M)53H4@@IJFOX"NOKBUX+7XM.:N&-@:*`4`RH!A^B`PHJ^IM)"A_,<2ZI-33O
M[>W:>NK80-C/\DD"OL^"I@DGSM:1XBOQ753#U4IVMJ00=ZMQ0>G8;-I!W=J]
M#KUZ()#S)('CD<%1Z"^3HDCB^V(/#'P0S$*"E92$K4I16$N**`*;4BA%#](%
M>@ZZ]3-+VT:YU?:OD%G;V[BZ,8GP"KI96"JM*&M.OKZ>FC0X0F,GS47F**1D
MCG&G200O3KTKI43TKNWK!4:4``'X`4(40!HBX3U*]E4JK]>X+4":=*;E)3V_
M#1%63V_#J:]N]>IZ$^NB+G1$:(C1$:(C1%P>Q[]CV[_V?GHBIJ%:T44D=R`D
MUZ=EBE.W[-$70$[&_H/J4_4"J@_V05V/UC_J]3HBKI)(!(H2`2.AH:=145!H
J=$7.B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1&B(T1?_9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
